

Vaccine Clinic Resource	ce for Immunizers
Title:	COVID-19, Influenza and Pneumococcal Vaccine Quick Reference Guide 2025/26
	Disclaimer: this Quick Reference Guide is not intended to replace other product specific vaccine references. The document is intended as a quick reference for frequently referred to information. Please refer to the
	product monographs and other resources online for all current and complete information.
Formulations:	COVID-19: mRNA Vaccine- Omicron LP.8.1 variant
	Flu: IIV3-SD: Inactivated Influenza Vaccine, Trivalent- Standard dose (egg-based)
	IIV3-HD: Inactivated Influenza Vaccine, Trivalent- High dose (egg-based)
	IIV3-Adj: Inactivated Influenza Vaccine, Trivalent- Adjuvanted (egg-based)
	IIV3-cc Inactivated Influenza Vaccine, Trivalent- Standard dose (mammalian cell culture-based)
	Pneumo: Pneumococcal 20-Valent Conjugate (Pneu-C-20) Vaccine
MB's 2025/26 Flu Vaccines	Egg-based vaccines:
Based on WHO's	• A/Victoria/4897/2022 (H1N1)pdm09-like virus
Recommended	A/Croatia/10136RV/2023 (H3N2)-like virus
Compositions:	B/Austria/1359417/2021 (B/Victoria lineage)-like virus
	Cell culture-based vaccines (Flucelvax®):
	A/Wisconsin/67/2022 (H1N1)pdm09-like virus
	A/District of Columbia/27/2023 (H3N2)-like virus
	B/Austria/1359417/2021 (B/Victoria lineage)-like virus
Product Monographs:	manitoba.ca/respiratoryviruses/resources-hcp.html#mono
Eligibility Criteria:	COVID-19: manitoba.ca/covid19/index.html
	Flu: manitoba.ca/health/flu/index.html
	Pneumo: manitoba.ca/health/publichealth/diseases/pneumococcal.html
Fact Sheets:	manitoba.ca/respiratoryviruses/resources-public.html
Canadian Immunization	COVID-19: www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html
Guide:	Influenza: www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-10-influenza-vaccine.html#a6
	Pneumo: www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html

	Spikevax ® <i>Moderna</i> mRNA Vaccine- Omicron LP.8.1 variant					
Product	Storage & Handling	Eligibility Criteria		Recommend	lations for Use	
Supplied: 12 years and older: 0.5 mL single dose prefilled	MULTIDOSE VIALS: Thaw time: 2° to 8°C (Refrigerator):	Immunization with the most updated COVID-19 vaccine is strongly recommended for previously vaccinated and unvaccinated individuals at increased risk of COVID-19 infection or severe	Age Range	COVID-19 Vaccination History	Schedule	Dose
syringe (10/box) OR 6 months and older:	 ≥ 2 hours 15° to 25° C (Room temperature): ≥ 45 min Do not refreeze. 	 disease: Adults 65 years of age or older Those 6 months of age and older who are: Residents of long-term care homes and other 	6 months- 4 years	Previously vaccinated Not previously vaccinated	1 dose 2-dose series at least 4 weeks apart	0.25ml
Royal Blue cap Coral Blue label 2.5 mL multidose vial	 Storage: Vials can be stored refrigerated between 2° to 8°C for up to 50 days prior to first use. Note: Day 1 is the day-to-fridge (aka "pick date"). Day 2 is the following day. Unpunctured vials may be stored between 8° to 25°C for up to 12 hours. 	congregate living settings Individuals with underlying medical conditions that place them at higher risk of severe COVID-19, including children with complex health needs	5-11 years	Not previously vaccinated OR previously vaccinated	1 dose	0.25ml
Number of doses per vial: 12 years and older: 5 doses of 0.5mL / vial OR 6 months to less than 12	 Unpunctured vials may be stored between 8° to 25°C for up to 12 hours. Discard time: 24 hours after first dose has been withdrawn if stored in refrigerator. 12 hours after first dose has been withdrawn if stored at room temperature. 	 Individuals who are pregnant Individuals in or from First Nations, Métis and Inuit communities Members of racialized and other equity-deserving communities 	12 years and older	Not previously vaccinated OR previously vaccinated	1 dose	0.5ml
years: 10 doses of 0.25mL / vial	After puncturing, you have a maximum of 24 hours (continuous, not cumulative) to keep it refrigerated, but the cumulative time outside the fridge must not exceed 12 hours. Once either of these limits are reached, the product should be	 People who provide essential community services All other previously vaccinated and unvaccinated individuals (6 	_	he updated formulation m nths from any previous CC	•	-
Do NOT require dilution.	discarded. Handling: Swirl the vial gently after thawing and between each withdrawal. Do not shake.	months of age and older) who are not at increased risk of COVID- 19 infection or severe disease (i.e., not on the list above) may receive the most recently updated vaccine.	are modera	If not previously vaccinated, individuals 6 months of age and older who are moderately to severely <u>immunocompromised</u> are eligible to receive additional doses. Refer to Table 1: <u>COVID-19 vaccines: Canadian</u>		gible to receive anadian
Inspect vials: White/off-white dispersion and may contain white or translucent product-related particulates. If solution contains foreign particulates or discoloration, do not administer.	SINGLE-DOSE PREFILLED SYRINGE: Thaw time: 2º to 8ºC (Refrigerator): Individual syringe: 1h 40 min Box of 10 syringes: 2h 40 min 15º to 25º C (Room temperature): Individual syringe: 40 min Box of 10 syringes: 1h 20 min Do not refreeze. Do not shake. Syringes should not be returned to the refrigerator after being thawed at room temperature. Storage: Refrigerated between 2° to 8°C for up to 50 days prior to first use. Discard time: 12 hours at room temperature (after removal from refrigerated conditions). Discard if not used within this time.	Medicinal ingredients: mRNA encoding SARS-CoV-2 spike protein, 5'(m7G-5'-ppp-5'-Gm) cap, 100 nucleotide 3' poly(A) tail Non-medicinal ingredients: Acetic acid, Cholesterol, DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), SM-102 (Heptadecan-9-yl 8-((2-hydroxyethyl) (6-oxo-6-(undecyloxy) hexyl) amino) octanoate), PEG2000-DMG (1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000), Sodium acetate trihydrate, Sucrose, Trometamol, Trometamol hydrochloride SPIKEVAX does not contain any preservatives, antibiotics, adjuvants, or human- or animal-derived materials. Does not contain natural rubber latex.	Route: Intr General Recomment infants & c Clinical judinjections. PHIMS DA' Agent list t dose of the	Immunization Guide - Canada.ca. A prescription is required for the additional doses. Route: Intramuscular (IM) 6 m to less than 12m of age: IM Anterolateral thigh		

2

Product	Storage & Handling	Eligibility Criteria	Recommendations for Use
Supplied: 12 years and older: 0.3mL single dose prefilled syringe (10/box) OR Gray cap & label 2.25 mL multidose vial (6 doses/vial) If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume. Do not pool excess vaccine from multiple vials. 5 to less than 12 years: Light blue cap & label 0.3mL single dose vial Do NOT require dilution. Inspect vials: The thawed suspension may contain white to off-white opaque amorphous particles. Do not administer if vaccine is discoloured or contains particulate matter.	SINGLE DOSE & MULTIDOSE VIALS: Thaw time: 2° to 8°C (Refrigerator): Single dose vials: A 10 vial pack of single dose vials may take 2 hours to thaw. Multiple dose vials: A 10 vial pack of multiple dose vials may take 6 hours to thaw. 15° to 25° C (Room temperature): 30 min Do not refreeze. Storage: Refrigerated between 2° to 8°C for up to 10 weeks prior to first use. Note: Day 1 is the day-to-fridge (aka "pick date"). Day 2 is the following day. Room temperature between 8° to 25°C for up to 12 hours prior to use. Discard time: 12 hours at room or refrigerated temperature after first	Immunization with the most updated COVID-19 vaccine is strongly recommended for previously vaccinated and unvaccinated individuals at increased risk of COVID-19 infection or severe disease: Adults 65 years of age or older Those 6 months of age and older who are: Residents of long-term care homes and other congregate living settings Individuals with underlying medical conditions that place them at higher risk of severe COVID-19, including children with complex health needs Individuals who are pregnant Individuals in or from First Nations, Métis and Inuit communities Members of racialized and other equity-deserving communities People who provide essential community services All other previously vaccinated and unvaccinated individuals (6 months of age and older) who are not at increased risk of COVID-19 infection or severe disease (i.e., not on the list above) may receive the most recently updated vaccine.	Dose: 0.3mL Schedule: 1 dose Route: Intramuscular (IM) Deltoid A dose of the updated formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation. If not previously vaccinated, individuals 6 months of age and older who are moderately to severely immunocompromised are eligible to receive additional doses. Refer to Table 1: COVID-19 vaccines: Canadian Immunization Guide - Canada.ca. A prescription is required for the additional doses. Recommended needle gauge and length: 22-
Before use, mix by inverting vaccine vial gently 10 times. Do not shake. Prior to mixing:	puncture. Handling: When at room temperature and between each withdrawal, mix by inverting vaccine vial gently 10 times. Do not shake .	Madicinal ingradients, mDNA encoding SADS CoV 2 chike protein E' [m37.2]	25G 1"-1 ½ " Clinical judgement should be used when selecting needle length for IM injections. Consider client's weight, age, and muscle mass.
 Gray cap vials: The thawed vaccine is a white to offwhite suspension and may contain white to off-white opaque amorphous particles. Blue cap vials: The thawed vaccine is a clear to slightly opalescent suspension and may contain white to off-white opaque amorphous particles. After mixing: Gray cap vials: The vaccine should appear as a white to off-white suspension with no visible particles. Blue cap vials: The vaccine should appear as a clear to slightly opalescent suspension with no visible particles. Do not use if liquid is discoloured or if particles are observed after mixing. 	SINGLE-DOSE PREFILLED SYRINGE: Storage: Refrigerated between 2°C to 8°C until the expiration date printed on the carton and syringe labels. Discard time: 12 hours at room temperature. After removing the tip cap and attaching an appropriate needle, the prefilled syringes should be used immediately. If it cannot be used immediately, it must be used within 4 hours.	Medicinal ingredients: mRNA encoding SARS-CoV-2 spike protein, 5' [m27,3'-OGppp(m12'-O)ApG] cap, 110-nucleotide 3' poly(A) tail with a 10-nucleotide linker sequence Non-medicinal ingredients: ALC-0315 = ((4-hydroxybutyl) azanediyl)bis (hexane-6,1-diyl)bis(2-hexyldecanoate), ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, cholesterol, DSPC = 1,2-distearoyl-sn-glycero-3-phosphocholine, sodium chloride, sucrose, tromethamine, tromethamine hydrochloride COMIRNATY does not contain preservative Does not contain natural rubber latex.	PHIMS DATA ENTRY: Select <i>COVID19-Pfizer</i> Comirnaty from the PHIMS Agent list to record vaccine administration.

Influenza	Flucelvax® Seqirus Ltd. IIV3-cc: 6 months of age and older			
Product	Storage and Handling	Eligibility Criteria	Recommendations for Use	
Supplied: 0.5 mL single dose prefilled syringe (10/box) Shake before use. After shaking, the normal appearance of the vaccine is a clear to slightly opalescent suspension. Visually inspect the contents of each pre-filled syringe for particulate matter and/or variation in appearance prior to administration. If either condition exists, do not administer the vaccine.	Storage: 2 to 8 degrees C° Do not freeze Discard product if exposed to freezing. Protect from light. Prefilled syringe is stable until expiry date.	Standard-dose influenza vaccine: all Manitobans 6 months of age and older who are registered with Manitoba Health Enhanced influenza vaccine: Adults aged 65 and older are eligible for an enhanced flu vaccine, refer to Fluzone®HD and Fluad® below An annual flu vaccine is especially important for those at increased risk of serious illness from the flu, their caregivers, and their close contacts. See the full list at: Seasonal Flu Health Province of Manitoba	6 months to 8 years of age: Dose: 0.5ml dose Route: 6 m to less than 12m of age: IM Vastus lateralis 12m and older: IM Deltoid Schedule: 1 or 2 doses Children 6m to 8 years of age who have not previously been vaccinated against influenza should receive a second dose at least 4 weeks later. Recommended Needle Gauge and Length: 22-25G 5/8"-1" 9 years of age and older: Dose: 0.5ml dose Route: IM Deltoid Schedule: 1 dose Recommended Needle Gauge and Length: 22-25G 1"-1 ½"	

Medicinal ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, prepared in cell cultures

Non-medicinal ingredients: Excipients: disodium phosphate dihydrate, magnesium chloride hexahydrate, potassium chloride, potassium dihydrogen phosphate, sodium chloride

Residuals: beta-propiolactone, cetyltrimethylammonium bromide, polysorbate 80

FLUCELVAX® pre-filled syringes contain no preservative or antibiotics. Does not contain natural rubber latex.

Influenza	Fluviral ID Biomedical Corporation of Quebec, IIV3-SD: 6 months of age and older			
Product	Storage and Handling	Eligibility Criteria	Recommendations for Use	
Supplied: 6 mL multidose vial (contains 5 mL of vaccine) 10 doses/vial Use a 1 mL syringe to withdraw 0.5mL dose The vaccine presents as an opalescent translucent to off- white suspension that may sediment slightly. The vial should be shaken prior to each administration and inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.	Storage: 2 to 8 degrees C° Do not freeze. Protect from light. The vaccine in multidose vials is stable for 13 months. Once punctured, the multidose vial should be discarded within 28 days. Between uses, the multidose vial should be stored in a refrigerator (2°C - 8°C).	Standard-dose influenza vaccine: all Manitobans 6 months of age and older who are registered with Manitoba Health Enhanced influenza vaccine: Adults aged 65 and older are eligible for an enhanced flu vaccine, refer to Fluzone®HD and Fluad® below An annual flu vaccine is especially important for those at increased risk of serious illness from the flu, their caregivers, and their close contacts. See the full list at: Seasonal Flu Health Province of Manitoba	6 months to 8 years of age: Dose: 0.5ml dose Route: → 6m to less than 12m of age: IM Vastus lateralis → 12m and older: IM Deltoid Schedule: 1 or 2 doses Children 6m to 8 years of age who have not previously been vaccinated against influenza should receive a second dose at least 4 weeks later. Recommended Needle Gauge and Length: 22-25G 5/8"-1" 9 years of age and older: Dose: 0.5ml dose Route: IM Deltoid Schedule: 1 dose Recommended Needle Gauge and Length: 22-25G 1"-1 ½"	

Medicinal ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, prepared from virus grown in the allantoic cavity of embryonated hens' eggs.

Non-medicinal ingredients: Egg proteins, ethanol, formaldehyde, phosphate buffered saline, polysorbate 80, sodium deoxycholate, α-tocopheryl hydrogen succinate, sucrose, thimerosal, Does not contain antibiotics.

Does not contain latex.

Influenza	Fluzone® Sanofi Pasteur Ltd., I	IV3-SD: 6 months of age and older	
Product	Storage and Handling	Eligibility Criteria	Recommendations for Use
Supplied: 0.5ml single dose prefilled syringes (10/box) OR 5 ml multidose vial (10 doses/vial) Shake well to uniformly distribute the suspension and inspect visually before each dose. After shaking well, solution is clear to slightly opalescent in colour. There should NOT be any particulate matter and/or discolouration- if these exist, do not administer.	Storage: 2 to 8 degrees C° Do not freeze Discard product if exposed to freezing. Protect from light. Once punctured, the multi-dose vial can be used until expiry date. A maximum of 10 doses can be withdrawn from a multidose vial. Unpunctured vial is stable until expiry date.	Standard-dose influenza vaccine: all Manitobans 6 months of age and older who are registered with Manitoba Health Enhanced influenza vaccine: Adults aged 65 and older are eligible for an enhanced flu vaccine, refer to Fluzone®HD and Fluad® below An annual flu vaccine is especially important for those at increased risk of serious illness from the flu, their caregivers, and their close contacts. See the full list at: Seasonal Flu Health Province of Manitoba	6 months to 8 years of age: Dose: 0.5ml dose Route: 6 m to less than 12m of age: IM Vastus lateralis 12m and older: IM Deltoid Schedule: 1 or 2 doses Children 6m to 8 years of age who have not previously been vaccinated against influenza should receive a second dose at least 4 weeks later. Recommended Needle Gauge and Length: 22-25G 5/8"-1" 9 years of age and older: Dose: 0.5ml dose Route: IM Deltoid Schedule: 1 dose Recommended Needle Gauge and Length: 22-25G 1"-1 ½"

Medicinal ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, propagated in embryonated chicken eggs. **Non-medicinal ingredients:** Phosphate buffered saline, egg protein, Triton® X-100, 0.01% w/v thimerosal is present in the multi-dose presentation only. *Does not contain latex*.

Influenza	Fluzone® High-Dose Sanofi Pasteur Ltd., IIV3-HD: 65 years of age and older			
Product	Storage and Handling	Eligibility Criteria	Recommendations for Use	
Supplied: 0.5ml single dose prefilled syringe (5/box) Shake well to uniformly distribute the suspension and inspect visually before administering each dose. After shaking the syringe, the liquid should be clear and slightly opalescent in color. Do not use if extraneous particulate matter and/or discoloration is observed.	Storage: 2 to 8 degrees C° Do not freeze Discard product if exposed to freezing Protect from light Do not use after the expiration date shown on the label	 Enhanced influenza vaccine: -Community dwelling individuals aged 80 years and older -Adults aged 65 years and older at highest risk of severe outcomes from influenza: residents of long-term care facilities (LTCF), including new and unimmunized residents admitted to an LTCF during flu season; residents of supported and assisted living facilities; clients in interim/transitional care beds. clients receiving homecare services while on a waiting list for admission into a LTCF; Indigenous Manitobans regardless of residence; people living in a remote/isolated community or north of the 53rd parallel of latitude; individuals in provincial correctional facilities, including those who are newly incarcerated or transferred from other federal or out-of-province correctional facilities. 	Dose: 0.5ml dose Route: IM Deltoid Schedule: 1 dose Recommended Needle Gauge and Length: 22-25G 1"-1 ½"	

Medicinal ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, propagated in embryonated chicken eggs. **Non-medicinal ingredients:** Formaldehyde, egg protein, Triton® X-100, phosphate buffered saline.

Does not contain antibiotics, gelatin, thimerosal, latex.

Influenza	Fluad ® <i>Seqirus Ltd.,</i> IIV3-Adj: 6	55 years of age and older	
Product	Storage and Handling	Eligibility Criteria	Recommendations for Use
Supplied: 0.5 mL single dose prefilled syringe (10/box)	Storage: 2 to 8 degrees C°	Enhanced influenza vaccine: -Community dwelling individuals aged 65-79	Dose: 0.5ml dose
Gently shake the contents of each syringe	Do not freeze Discard product if exposed to	years and older (that do not fall under the highest risk criteria for Fluzone®HD)	Route: IM Deltoid
and inspect for the presence of particulate matter.	freezing	ingliest risk circula for riuzone fib)	Schedule: 1 dose
F	Protect from light		Recommended Needle Gauge and Length:
After shaking, the normal appearance of	Ü		22-25G 1"-1 ½"
FLUAD® is a milky-white suspension.	Do not use after the expiration date shown on the label		
If there are visible particles, allow the			
vaccine to come to room temperature	FLUAD® can be administered		
and shake before use.	following a 2-hour exposure at temperatures between 8° and		
Do not use the vaccine if particles remain or if it is discoloured.	25°C. This is not, however, a recommendation for storage.		

Medicinal ingredients: Influenza virus haemagglutinin surface antigens

Non-medicinal ingredients: Adjuvant (MF59C.1): citric acid, polysorbate 80, sodium citrate, sorbitan trioleate, Squalene. Excipients: calcium chloride dehydrate, disodium phosphate dehydrate, magnesium chloride hexahydrate, potassium chloride, potassium dihydrogen phosphate, sodium chloride. The vaccine may contain trace amounts of the following: cetyltrimethylammonium bromide (CTAB) (residual), formaldehyde (residual), hydrocortisone (trace), kanamycin (trace), neomycin (trace), ovalbumin (egg protein, residual).

Does not contain latex.

Pneumo	Prevnar [®]	20 Pfizer, Pneu-C-20: 65 years of age and old	er and those at high risk of IPD who meet the Ma	anitoba Health Eligibility Criteria
Product		Storage and Handling	Eligibility Criteria	Recommendations for Use
Supplied: 0.5ml single dose pasyringes (10/box) A white deposit and clear supplied and be observed in the prefixed syringe containing the suspension. Shake vigorously until the conthe syringe are a homogened suspension. Do not use the vicannot be re-suspended. Visually inspect the vaccine for particulate matter and discoluption to administration. Do not large particulate matter or dissipation.	pernatant filled nsion. Intents of ous white vaccine if it for large loration oot use if	Storage: 2 to 8 degrees C° Do not freeze Discard if vaccine has been frozen. Do not use after the expiration date shown on the label Store syringes in the refrigerator horizontally (laying flat on shelf) to minimise the redispersion time. Use as soon as possible after being removed from refrigeration. Prevnar 20® can be administered provided total (cumulative multiple excursions) time out of refrigeration (at temperatures between 8°C and 25°C) does not exceed 96 hours.	 65 years of age and older and individuals 2 months and older at high risk of IPD who meet the Manitoba Health Eligibility Criteria All adults ≥ 65 years of age are eligible to receive 1 dose if they have not yet received Pneu-P-23 since turning 65 years old. Those that received a dose of Pneu-P-23 before turning 65 can receive a dose of Pneu-C-20 5 years after that dose. Those that received a dose of Pneu-P-23 since turning 65 AND are at high risk of IPD can receive a dose 5 years after that dose. 	Dose: 0.5ml Route: ➤ 2m to less than 12m of age: IM Anterolateral thigh ➤ 12m and older: IM Deltoid Schedule: 1 dose Additional doses may be recommended for those at highest risk. This should be assessed by the health care provider. Recommended Needle Gauge and Length: IM: 22-25G 1"-1 ½" (5/8"-1" for infants & children)
		Cumulative multiple excursions between 0°C and 2°C are also permitted if the total time between 0°C and 2°C does not exceed 72 hours. These are not, however, recommendations for		

Medicinal ingredients: S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F saccharides, 6B saccharide, CRM197 carrier protein Non-medicinal ingredients: Aluminum phosphate, polysorbate 80, sodium chloride, succinic acid

Does not contain latex.

storage.